State Street
MLYS icon

State Street’s Mineralys Therapeutics MLYS Stock Holding History

State Street’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79.5M Sell
2,935,940
-249,059
-8% -$7.3M ﹤0.01% 1502
2025
Q4 		$116M Buy
3,184,999
+1,881,976
+144% +$75.5M ﹤0.01% 1272
2025
Q3 		$49.4M Sell
1,303,023
-140,536
-10% -$3.04M ﹤0.01% 1729
2025
Q2 		$19.5M Buy
1,443,559
+923,379
+178% +$13.4M ﹤0.01% 2199
2025
Q1 		$8.26M Buy
520,180
+15,647
+3% +$180K ﹤0.01% 2651
2024
Q4 		$6.21M Buy
504,533
+20,767
+4% +$272K ﹤0.01% 2870
2024
Q3 		$5.86M Buy
483,766
+18,627
+4% +$225K ﹤0.01% 2888
2024
Q2 		$5.44M Buy
465,139
+159,453
+52% +$2.01M ﹤0.01% 2891
2024
Q1 		$3.95M Buy
305,686
+23,602
+8% +$291K ﹤0.01% 3019
2023
Q4 		$2.43M Buy
282,084
+52,107
+23% +$409K ﹤0.01% 3251
2023
Q3 		$2.19M Buy
229,977
+18,780
+9% +$245K ﹤0.01% 3289
2023
Q2 		$3.6M Buy
211,197
+76,397
+57% +$1.14M ﹤0.01% 3159
2023
Q1 		$2.11M Buy
+134,800
New +$2.27M ﹤0.01% 3321

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street's MLYS Position: Q1 2026 in Review

State Street reduced its Mineralys Therapeutics (MLYS) stake by 7.8% in Q1 2026, selling an estimated $7.3M and leaving 2,935,940 shares worth $79.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1502.

State Street first reported a position in MLYS in Q1 2023 and has held it in 13 quarters since. The position peaked at $116M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • State Street held 2,935,940 shares of Mineralys Therapeutics worth $79.5M as of Q1 2026.
  • State Street sold 249,059 Mineralys Therapeutics shares in Q1 2026, an estimated $7.3M.
  • Mineralys Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1502 holding.
  • State Street first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • State Street's Mineralys Therapeutics position peaked at $116M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.